Unlocking the path to efficient H. pylori eradication: Embracing potassium-competitive acid blockers (P-CABs)

Saudi J Gastroenterol. 2023 Nov-Dec;29(6):323-325. doi: 10.4103/sjg.sjg_297_23.

Authors

Thomas J Borody¹, John Ng², Sibasish Dolai³

Affiliations

¹ Department of Gastroenterology, The Centre for Digestive Diseases (CDD), Sydney, NSW, Australia.
² Axent Medical Pty Ltd., Sydney, NSW, Australia.
³ Department of Gastroenterology, The Centre for Digestive Diseases (CDD); Axent Medical Pty Ltd., Sydney, NSW, Australia.

No abstract available

Publication types

Editorial

MeSH terms

Amoxicillin / therapeutic use
Anti-Bacterial Agents / therapeutic use
Clarithromycin / therapeutic use
Drug Therapy, Combination
Helicobacter Infections* / drug therapy
Helicobacter Infections* / epidemiology
Helicobacter pylori* / drug effects
Humans
Potassium
Proton Pump Inhibitors / therapeutic use
Treatment Outcome

Substances

Amoxicillin
Anti-Bacterial Agents
Clarithromycin
Potassium
Proton Pump Inhibitors